Resumen de Investigación
BL21 probiotic improves glycemic control in type 2 diabetes patients
Moderate confidence
Low bias
Última actualización 18 de junio de 2026Conclusión Clave:
This study evaluated the efficacy and safety of Bifidobacterium longum subsp. longum BL21 as an adjunctive therapy to metformin in patients with type 2 diabetes, finding a significant reduction in HbA1c levels.
Estudio de un Vistazo
Participantes
Intervención
Bifidobacterium longum subsp. longum BL21, Placebo
Resultados
HbA1c, fasting blood glucose (FBG), insulin resistance (HOMA-IR), lipid profiles, gut microbiota composition, HbA1c levels (Placebo)
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
Supplementation with BL21 led to a significant reduction in HbA1c levels (p = 0.026).
Non-significant trends toward reduction were observed for fasting blood glucose.
Gut microbiota analysis revealed an increase in beneficial genera, including Bifidobacterium and Faecalibacterium.
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Bifidobacterium longum subsp. longum BL21 (Supplements) |  Fasting blood sugar (FBS) (Glycemic Control) | No Change | Unclear |
Bifidobacterium longum subsp. longum BL21 (Supplements) |  gut microbiota composition (Metabolic Health) | Increase | Strong |
Bifidobacterium longum subsp. longum BL21 (Supplements) | HbA1c (Glycemic Control) | Decrease | Strong |
Bifidobacterium longum subsp. longum BL21 (Supplements) | Insulin resistance (Metabolic Health) | No Change | Unclear |
Bifidobacterium longum subsp. longum BL21 (Supplements) | lipid profiles (Metabolic Health) | No Change | Unclear |
 Placebo (Medications) | HbA1c levels (Placebo) (Glycemic Control) | No Change | Unclear |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
La Evidencia Sugiere
- HbA1c levels decreased by 0.3% in the intervention group (p = 0.026).
- No significant change in HbA1c levels was observed in the placebo group.
- Trends toward improvement in fasting blood glucose and insulin resistance were noted.
A quién se aplica
- Adults diagnosed with type 2 diabetes mellitus.
- Patients currently receiving metformin therapy.
Tener en Cuenta
- Results may not apply to populations outside the study's demographic.
- The study did not measure long-term effects beyond the trial duration.
- Further research is needed to confirm the findings and explore mechanisms.
Entre Líneas
- The study's sample size may limit the generalizability of the findings.
- Non-significant trends in other outcomes suggest further research is needed.
- The study duration may not be sufficient to assess long-term effects.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Referencia de la Revista
Chengsheng Z, Yinhua L, Yanyan C, et al. Efficacy and Safety of Bifidobacterium longum subsp. longum BL21 as an Adjunctive Therapy to Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. Food Science & Nutrition. 2026;14(1):e71437. doi:10.1002/fsn3.71437
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on Probiotics and Synbiotics and gut microbiota composition, Probiotics and Synbiotics and Glycemic Control.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Glycemic Control Evidence Hub
All studies measuring Glycemic Control
1 studies
outcome_hubMeasures Glycemic Control as a key outcome.
gut microbiota composition Evidence Hub
All studies measuring gut microbiota composition
1 studies
outcome_hubMeasures gut microbiota composition as a key outcome.
Probiotics and Synbiotics Evidence Hub
All studies on Probiotics and Synbiotics
1 studies
intervention_hubContributes to Probiotics and Synbiotics evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Bifidobacterium longum subsp. longum BL21 and gut microbiota composition
Intervention: Bifidobacterium longum subsp. longum BL21Outcome: gut microbiota composition
1 results
All studies on Bifidobacterium longum subsp. longum BL21 and HbA1c
Intervention: Bifidobacterium longum subsp. longum BL21Outcome: HbA1c
1 results
All studies on Bifidobacterium longum subsp. longum BL21
Intervention: Bifidobacterium longum subsp. longum BL21
1 results
All studies measuring gut microbiota composition
Outcome: gut microbiota composition
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
Preguntas que esta evidencia ayuda a responder
Key clinical and research questions this study contributes to.
Does bifidobacterium longum subsp. longum bl21 improve gut microbiota composition?
Based on connected evidence for Bifidobacterium longum subsp. longum BL21 and gut microbiota composition.
Does bifidobacterium longum subsp. longum bl21 affect HbA1c in people with diabetes?
Exploring evidence on Bifidobacterium longum subsp. longum BL21 and HbA1c outcomes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.